Nature Communications (Mar 2022)

Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine

  • Myriam Arévalo-Herrera,
  • Xiomara Gaitán,
  • Michelle Larmat-Delgado,
  • María Alejandra Caicedo,
  • Sonia M. Herrera,
  • Juliana Henao-Giraldo,
  • Angélica Castellanos,
  • Jean-Christophe Devaud,
  • André Pannatier,
  • José Oñate,
  • Giampietro Corradin,
  • Sócrates Herrera

DOI
https://doi.org/10.1038/s41467-022-29226-3
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

In this phase 2 clinical trial, the authors assess protective efficacy of a Plasmodium vivax circumsporozoite vaccine in naïve and semi-immune individuals from controlled human malaria infection as well as antibody and IFN-γ response to vaccination.